You can rely on decades of past experience of VivaQuant's staff in providing products and services to help pharmaceutical companies and medical device firms bring products to market faster and more predictably. We understand the regulatory and compliance landscape and can help you navigate the sometimes tortuous path to assessing the cardiac safety of your product.
Whether you need to assess interval changes, arrhythmia liability, arrhythmia burden, or restitution, VivaQuant is committed to providing the most accurate results possible, in the shortest time, and at a cost-effective price. We are a preferred ECG core lab partner for:
The Rhythm ExpressTM platform is the engine that drives the proven accuracy of our ECG core lab services. The key enabler of the accuracy and efficiency provided by Rhythm Express is our patented Multi-Domain Signal Processing (MDSPTM) wavelet-based analytics. MDSP removes up to 95 percent of noise in ambulatory ECGs without distorting morphology, resulting in improved arrhythmia detection accuracy and reduced variability in cardiac interval (e.g., QT) measurements. By eliminating the noise, MDSP provides a more reliable and stable feature set as an input for machine learning, enabling superb accuracy and repeatability.
We provide concentration effects modeling for customers desiring to obtain a thorough QT (TQT) waiver, or for full TQT studies. A recent publication in Clinical Pharmacology and Therapeutics documents the performance of our interval measurement algorithm and concentration effects models, demonstrating a 22 percent improvement in accuracy. This additional accuracy could potentially facilitate a clear decision on arrhythmia liability vs. a less accurate result that may lead to additional expensive studies or lack of FDA approval to proceed. Click here for a copy of the paper.